These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 18586926)

  • 1. FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma.
    Cohen MH; Johnson JR; Justice R; Pazdur R
    Oncologist; 2008 Jun; 13(6):709-14. PubMed ID: 18586926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia/lymphoma.
    Cohen MH; Johnson JR; Massie T; Sridhara R; McGuinn WD; Abraham S; Booth BP; Goheer MA; Morse D; Chen XH; Chidambaram N; Kenna L; Gobburu JV; Justice R; Pazdur R
    Clin Cancer Res; 2006 Sep; 12(18):5329-35. PubMed ID: 17000665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nelarabine: a novel purine antimetabolite antineoplastic agent.
    Buie LW; Epstein SS; Lindley CM
    Clin Ther; 2007 Sep; 29(9):1887-99. PubMed ID: 18035189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.
    DeAngelo DJ
    Hematol Oncol Clin North Am; 2009 Oct; 23(5):1121-35, vii-viii. PubMed ID: 19825456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of nelarabine in patients with relapsed or refractory T-ALL/T-LBL.
    Horibe K; Takimoto T; Yokozawa T; Makimoto A; Kobayashi Y; Ogawa C; Ohno R; Koh N; Katsura K; Tobinai K
    Rinsho Ketsueki; 2011 Jun; 52(6):406-15. PubMed ID: 21737993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies.
    Kurtzberg J; Ernst TJ; Keating MJ; Gandhi V; Hodge JP; Kisor DF; Lager JJ; Stephens C; Levin J; Krenitsky T; Elion G; Mitchell BS
    J Clin Oncol; 2005 May; 23(15):3396-403. PubMed ID: 15908652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nelarabine: efficacy in the treatment of clinical malignancies.
    Roecker AM; Allison JC; Kisor DF
    Future Oncol; 2006 Aug; 2(4):441-8. PubMed ID: 16922610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group.
    Berg SL; Blaney SM; Devidas M; Lampkin TA; Murgo A; Bernstein M; Billett A; Kurtzberg J; Reaman G; Gaynon P; Whitlock J; Krailo M; Harris MB;
    J Clin Oncol; 2005 May; 23(15):3376-82. PubMed ID: 15908649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nelarabine: new drug. T-lymphoblastic leukaemia/lymphoma: more evaluation needed.
    Prescrire Int; 2009 Feb; 18(99):3-5. PubMed ID: 19382393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clofarabine and nelarabine: two new purine nucleoside analogs.
    Gandhi V; Plunkett W
    Curr Opin Oncol; 2006 Nov; 18(6):584-90. PubMed ID: 16988579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation.
    Gökbuget N; Basara N; Baurmann H; Beck J; Brüggemann M; Diedrich H; Güldenzoph B; Hartung G; Horst HA; Hüttmann A; Kobbe G; Naumann R; Ratei R; Reichle A; Serve H; Stelljes M; Viardot A; Wattad M; Hoelzer D
    Blood; 2011 Sep; 118(13):3504-11. PubMed ID: 21715318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single high dose of idarubicin combined with high-dose ABA-C (MSKCC ALL-3 protocol) in adult and pediatric patients with acute lymphoblastic leukemia. Experience at the University La Sapienza of Rome.
    Testi AM; Moleti ML; Giona F; Annino L; Chiaretti S; Del Giudice I; Todisco E; D'Elia G; Ferrari A; Arcese W; Mandelli F
    Haematologica; 1997; 82(5 Suppl):19-22. PubMed ID: 9402749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.
    Mann BS; Johnson JR; Cohen MH; Justice R; Pazdur R
    Oncologist; 2007 Oct; 12(10):1247-52. PubMed ID: 17962618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group.
    Burkhardt B; Reiter A; Landmann E; Lang P; Lassay L; Dickerhoff R; Lakomek M; Henze G; von Stackelberg A
    J Clin Oncol; 2009 Jul; 27(20):3363-9. PubMed ID: 19433688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nelarabine (Arranon) for T-cell acute lymphoblastic leukemia.
    Med Lett Drugs Ther; 2006 Feb; 48(1228):14-5. PubMed ID: 16467734
    [No Abstract]   [Full Text] [Related]  

  • 16. Nelarabine: a nucleoside analog with efficacy in T-cell and other leukemias.
    Kisor DF
    Ann Pharmacother; 2005 Jun; 39(6):1056-63. PubMed ID: 15870141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma.
    Kadia TM; Gandhi V
    Expert Rev Hematol; 2017 Jan; 10(1):1-8. PubMed ID: 27869523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia: literature review and own experience.
    Dyakonova YY; Bydanov OI; Popov AM; Olshanskaya YV; Boichenko EG; Aleynikova OV; Maschan MA; Shelikhova LN; Litvinov DV; Khachatryan LA; Ponomareva NI; Fechina LG; Novichkova GA; Pashanov ED; Karachunskiy AI
    Ter Arkh; 2018 Aug; 90(7):38-50. PubMed ID: 30701921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension.
    Kaminskas E; Farrell AT; Wang YC; Sridhara R; Pazdur R
    Oncologist; 2005 Mar; 10(3):176-82. PubMed ID: 15793220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia.
    Jeha S; Gaynon PS; Razzouk BI; Franklin J; Kadota R; Shen V; Luchtman-Jones L; Rytting M; Bomgaars LR; Rheingold S; Ritchey K; Albano E; Arceci RJ; Goldman S; Griffin T; Altman A; Gordon B; Steinherz L; Weitman S; Steinherz P
    J Clin Oncol; 2006 Apr; 24(12):1917-23. PubMed ID: 16622268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.